Sarcoid-like reaction mimicking nodal progression after neoadjuvant pembrolizumab-based chemoimmunotherapy in non-small cell lung cancer: a case report

Read full text Summarise with VIRAT
Authors: Ikki Takada, Takuya Nagashima, Yui Kaburaki, Ryotaro Matsuyama, Chiaki Kanno, Seigo Katakura, Kota Washimi, Tetsuya Isaka, Shuji Murakami, Tomoyuki Yokose, Hiroyuki Ito
Cited by: 0
References: 8

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Background Combining chemotherapy with immune checkpoint inhibitors (ICIs) has improved the resectability and survival in patients with resectable non-small cell lung cancer. Increasing ICI use has led to increasing recognition of immune-related adverse events, including drug-induced sarcoid-like reactions (DISR). DISR are uncommon and manifest as non-caseating granulomatous inflammation which may mimic disease progression on imaging. Differentiating DISR from true progression is essential to avoid inappropriate changes in plans for curative treatment. Case presentation A 44-year-old man with Stage IIIA (cT2bN2aM0) right upper lobe lung adenocarcinoma underwent four cycles of carboplatin, paclitaxel, and pembrolizumab as neoadjuvant therapy. Post-treatment imaging showed bilateral enlargement and increased fluorodeoxyglucose uptake in the hilar and mediastinal lymph nodes, and regression of the primary tumor and #11s node. Although these findings were initially interpreted as progressive disease, a sarcoid-like reaction was suspected. Preoperative endobronchial ultrasound-guided transbronchial needle aspiration of the #7 node showed granulomatous changes without signs of malignancy. Intentional first dissection of the #7 node and frozen section analysis during surgery confirmed these findings. The patient subsequently underwent right upper lobectomy with ND2a-2 lymph node dissection. The final pathology revealed ypT1cN0M0 solid adenocarcinoma and granulomatous findings consistent with DISR. Conclusion This case demonstrates the importance of cautious interpretation of nodal enlargement after immunotherapy. Bronchoscopic evaluation and intraoperative pathological evaluation ruled out progression and enabled curative surgery. When hilar lymph node enlargement is encountered after ICI therapy, clinicians should consider the possibility of DISR and perform appropriate pathological evaluation to ensure accurate disease staging.

Fields of Study & Subjects

Cancer Immunotherapy and Biomarkers Sarcoidosis and Beryllium Toxicity Research Lung Cancer Diagnosis and Treatment

Publication details

Journal / source
International Journal of Lung Cancer
Volume
1
Issue
2
Pages
100021–100021
Publication date
27 March 2026
Language
EN